HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Senate Appropriators Call For Botanical Identity Testing Guidance

This article was originally published in The Tan Sheet

Executive Summary

A Senate FDA appropriation report says the guidance would enhance the agency’s ability to inspect and assess industry practices for manufacturing botanical dietary supplements. A National Center for Natural Products Research official says most botanical ingredients lack standard identity tests.

You may also be interested in...



DMAA Warnings Shed Light On FDA NDI Enforcement

FDA’s warning letters to 10 marketers of DMAA-containing products might have a silver lining for the supplement industry as they suggest the agency may be flexible on its controversial interpretation of some provisions in the new dietary ingredient notification requirement.

Reps Threaten Legislation To Align NDI Guidance With DSHEA

The letter from the office of caucus co-chair Rep. Burton says the House members contacted FDA following the agency’s “dismissal” of a Senate request to withdraw or revise the NDI draft guidance. Rep. Ron Paul, a candidate for the GOP nomination for president, also signed the letter.

Consumers Challenge DMAA Safety After DOD Bans Products

Complaints against GNC Holdings Inc., manufacturer Cellucor Sports Nutrition and Woodbolt Distribution and against USPLabs rely on DOD’s decision to ban sales of the product at military exchanges and moves by Canadian regulators to support their arguments.

Related Content

Topics

Latest News
UsernamePublicRestriction

Register

RS125139

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel